RxDoctor Payments Data

Tshiswaka Kayembe, MD

Cardiovascular Disease · Saint Louis, MONPI 1164477766

Payments from drug & device makers

$6,725in general payments, 2019–2025

Across 69 payments — averaging $97.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$3K
  • Medtronic$2K
  • Abbott$1K
  • Impulse Dynamics (USA) Inc.$369
  • Amgen$133
  • Novartis$109
  • plus $111 from 6 others

What the payments were for

  • Consulting fees$1182%
  • Travel & lodging$4,61469%
  • Food & beverage$1,93629%
  • Education$451%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,725 in reported general payments places this provider in the 65th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$132,284
Medicare patients
899
Services billed
2,266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban103$86,765
EntrestoSacubitril/Valsartan47$34,012
XareltoRivaroxaban34$20,266
JanumetSitagliptin Phos/Metformin Hcl11$6,343
Clonidine13$1,765
Diltiazem 24hr Er (Cd)Diltiazem Hcl15$1,217
Potassium Chloride49$1,148
Isosorbide Mononitrate ErIsosorbide Mononitrate129$1,105
Digoxin54$1,053
Metoprolol Tartrate196$845
ClopidogrelClopidogrel Bisulfate101$777
Ranolazine ErRanolazine13$709
Atorvastatin Calcium73$701
Bumetanide16$552
Furosemide103$529

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$86,765103 claims
NovartisEntresto$109$34,01247 claims
Johnson & JohnsonXarelto$18$20,26634 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →